Safety, immunogenicity, and protective effective of inhaled COVID‐19 vaccines: A systematic review and meta‐analysis
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29625 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Gao Song und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Puer People's Hospital, Pu'er, China. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19, Antibodies, Neutralizing, Antibodies, Viral. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Yunnan Provincial Science and Technology Department.
Abstract (Originalsprache)
This study aimed to examine the safety, immunogenicity and protective effective of inhaled COVID‐19 vaccines (ICVs). Literature research was done through EMBASE, Cochrane, PubMed, and Web of Science up to 10 March 2024. Pooled estimates with corresponding 95% confidence intervals (CI) were computed and compared using the random effects and common effects model. Of the 15 studies, 11 analyzed safety, 13 analyzed immunogenicity, and 3 analyzed protective effective. The results showed a favorable safety profile of ICVs for primary vaccination series, however it does not always seem to produce the expected immune response and protective effective. Meta‐analysis of ICVs booster vaccinations (BVs) showed that the levels of neutralizing antibody Geometric mean titer (nAb‐GMT) with aerosolised Ad5‐nCoV (AAd5‐nCoV) were all higher than those with inactivated vaccine (INA‐nCoV) (standard mean difference (SMD) = 2.32; 95% CI: 1.96–2.69) and intramuscular Ad5‐nCoV (IMAd5‐nCoV) (SMD = 0.31; 95% CI: 0.14–0.48) against the original strain of SARS‐CoV‐2. Importantly, we also observed similar results in the omicron variant. In addition, ICV in BVs has high mucosal immunity to IgA antibodies. The risk of adverse events was comparable or lower for AAd5‐nCoV compared to INA‐nCoV or IMAd5‐nCoV. Current evidence shows that the safety profile of ICVs were well. The booster dose of AAd5‐nCoV had a high immune response (including mucosal immunity) and provided protection against COVID‐19 caused by the SARS‐CoV‐2 omicron variant. Further studies are needed to investigate the long‐term safety of intranasal vaccine booster protection and various types of ICVs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Puer People's Hospital, Pu'er, China.
- Department of Reproductive Medicine, Puer People's Hospital, Pu'er, China.
ORCID-Profile: Gao Song, Meng-Qun Cheng
Förderung
- Yunnan Provincial Science and Technology Department
Zitieren
APA
Song, G., Li, R., & Cheng, M. Q. (2024). Safety, immunogenicity, and protective effective of inhaled COVID‐19 vaccines: A systematic review and meta‐analysis. Journal of Medical Virology. https://doi.org/10.1002/jmv.29625
Vancouver
Song G, Li R, Cheng MQ. Safety, immunogenicity, and protective effective of inhaled COVID‐19 vaccines: A systematic review and meta‐analysis. Journal of Medical Virology. 2024. doi:10.1002/jmv.29625
BibTeX
@article{Song2024,
author = {Song, Gao and Li, Rong and Cheng, Meng-Qun},
title = {Safety, immunogenicity, and protective effective of inhaled COVID‐19 vaccines: A systematic review and meta‐analysis},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29625}
}
EUVIMED